Deferoxamine mesylate enhances virulence of community-associated methicillin resistant Staphylococcus aureus

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Staphylococcus aureus, particularly community-associated methicillin-resistant strains (CA-MRSA) like USA300, are significant causes of bacterial infections.
• Iron is essential for bacterial growth and virulence.
• Deferoxamine mesylate (DFO) is a chelating agent used to treat iron overload but can also impact microbial iron metabolism.

Purpose of the Study:

• To investigate whether Staphylococcus aureus USA300 can utilize deferoxamine mesylate (DFO) as an iron source.
• To determine the in vivo impact of DFO administration on USA300 infection severity and bacterial burden in a murine model.

Main Methods:

• In vitro assessment of DFO's effect on USA300 growth and iron uptake.
• In vivo murine model of USA300 infection with and without DFO administration (intraperitoneal).
• Evaluation of bacterial burden in liver and kidneys, abscess formation, and tissue damage.

Main Results:

• Staphylococcus aureus USA300 demonstrated the ability to acquire iron from DFO.
• Mice treated with DFO exhibited significantly higher bacterial loads in the liver and kidneys compared to untreated controls.
• DFO administration was associated with increased abscess formation and tissue destruction in infected organs.
• Mutants of USA300 deficient in DFO uptake did not show increased virulence when treated with DFO.

Conclusions:

• The study reveals a novel mechanism where CA-MRSA USA300 exploits the iron chelation therapy drug DFO for its own benefit.
• DFO treatment can exacerbate USA300 infections in vivo, highlighting a potential therapeutic challenge.
• Targeting DFO uptake pathways in USA300 may represent a strategy to mitigate DFO-associated increases in virulence.